Actinium Pharmaceuticals Inc Share Price Today: Live Updates & Key Insights

Actinium Pharmaceuticals Inc share price today is $1.11, up 1.83%. The stock opened at $1.07 against the previous close of $1.09, with an intraday high of $1.14 and low of $1.06.

Actinium Pharmaceuticals Inc Share Price Chart

Actinium Pharmaceuticals Inc

us-stock
To Invest in {{usstockname}}
us-stock

Actinium Pharmaceuticals Inc Share Price Performance

$1.11 0.0183(1.83%) ATNM at 23 Mar 2026 12:05 PM Biotechnology
Lowest Today 1.06
Highest Today 1.14
Today’s Open 1.07
Prev. Close 1.09
52 Week High 2.41
52 Week Low 1.02
Day’s Range: Low 1.06 High 1.14
52-Week Range: Low 1.02 High 2.41
1 day return -
1 Week return -0.89
1 month return +5.71
3 month return -31.05
6 month return -31.26
1 year return -25.0
3 year return -87.88
5 year return -87.41
10 year return -

Actinium Pharmaceuticals Inc Institutional Holdings

Actinium Pharmaceuticals Inc Market Status

Strong Buy: 2

Buy: 2

Hold: 1

Sell: 0

Strong Sell: 0

Actinium Pharmaceuticals Inc Fundamentals

Market Cap 34.63 M

PB Ratio 2.5121

PE Ratio 0.0

Enterprise Value -17.62 M

Total Assets 76.90 M

Volume 177574

Actinium Pharmaceuticals Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:1030000 1.0M, FY21:1144000 1.1M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:1030000 1.0M, FY21:1144000 1.1M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-50141000 -50.1M, FY22:-31930000 -31.9M, FY21:-24584000 -24.6M, FY20:-22037000 -22.0M, FY19:-21726661 -21.7M

Quarterly Revenue Q3/2025:90000 0.1M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-116000 -0.1M, Q2/2025:-204000 -0.2M, Q1/2025:-205000 -0.2M, Q3/2024:null 0.0M, Q2/2024:-189000 -0.2M

Quarterly Net worth Q3/2025:-5131000 -5.1M, Q2/2025:-6878000 -6.9M, Q1/2025:-15938000 -15.9M, Q3/2024:-11568000 -11.6M, Q2/2024:-11353000 -11.4M

About Actinium Pharmaceuticals Inc & investment objective

Company Information Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a preclinical non-prostate specific-membrane antigen targeting radiotherapy utilizing the Actinium-225 radioisotope for patients with prostate cancer. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.

Organisation Biotechnology

Employees 25

Industry Biotechnology

CEO Mr. Sandesh C. Seth M.B.A., M.S.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Actinium Pharmaceuticals Inc FAQs

What is the share price of Actinium Pharmaceuticals Inc today?

The current share price of Actinium Pharmaceuticals Inc is $1.11.

Can I buy Actinium Pharmaceuticals Inc shares in India?

Yes, Indian investors can buy Actinium Pharmaceuticals Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Actinium Pharmaceuticals Inc shares in India?

You can easily invest in Actinium Pharmaceuticals Inc shares from India by:

Can I buy fractional shares of Actinium Pharmaceuticals Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Actinium Pharmaceuticals Inc?

Actinium Pharmaceuticals Inc has a market cap of $34.63 M.

In which sector does Actinium Pharmaceuticals Inc belong?

Actinium Pharmaceuticals Inc operates in the Biotechnology sector.

What documents are required to invest in Actinium Pharmaceuticals Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Actinium Pharmaceuticals Inc?

The PE ratio of Actinium Pharmaceuticals Inc is N/A and the PB ratio is 2.51.